CardioFocus HeartLightâ„¢ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011
MARLBOROUGH, Mass., June 22, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced today that its technology will be the subject of several scientific sessions at the upcoming European Heart Rhythm Association (EHRA) EUROPACE 2011 congress, June 26-29 in Madrid, Spain.
HeartLight EAS is a unique catheter ablation technology that incorporates an endoscope and illumination to provide physicians with direct visualization within a beating heart, in real time and without radiation. It features a compliant, dynamically adjustable balloon catheter for improved contact with the pulmonary vein (PV) ostium and utilizes laser energy for more efficient, precise ablation. Recent data has demonstrated that approximately 86% of PVs remained persistently isolated after three months following a single procedure with HeartLight EAS, with 65% of patients achieving durable freedom from AF.
"Clinical results with HeartLight EAS throughout Europe have been very promising, and we are excited to showcase our technology at EUROPACE, where catheter ablation will be a major conference topic," commented Stephen Sagon, President and CEO of CardioFocus, Inc. "We are encouraged by the adoption of the technology by numerous cardiology thought leaders, many of whom are presenting at this congress, and expect to broaden the use of the system in Europe as a new treatment option for atrial fibrillation patients."
The HeartLight technology will be featured in the following EUROPACE 2011 sessions:Mini-Satellite Symposium – "Pulmonary vein isolation for atrial fibrillation using the laser balloon endoscopic ablation system," Monday, June 27
Chaired by Vivek Y. Reddy, MD, of Mount Sinai School of Medicine, New York, USA and featuring presentations by Claudio Tondo, MD, PhD, of Centro Cardiologico Monzino, Milan, Italy and Julian Chun, MD,